Fig. 6: OTUD5 knockdown combined with everolimus inhibits bladder cancer growth in vitro and in vivo.
From: Deubiquitinase OTUD5 modulates mTORC1 signaling to promote bladder cancer progression
A Colony formation assays and quantification results of UM-UC-14/WT and UM-UC-14/shOTUD5 cells treated with or without everolimus (10 nM). **P < 0.01, ***P < 0.001. B The growth curves of UM-UC-14/WT and UM-UC-14/shOTUD5 cells treated with or without everolimus (10 nM). ***P < 0.001. C The growth curves of xenografts in different treatment groups. Tumor volumes were measured every three days from day 12 to day 30. ***P < 0.001. D Illustration of tumors excised from male nude mice in each treatment group. E After 30 days, the nude mice were sacrificed, and UM-UC-14 cell xenografts were weighed. **P < 0.01, ***P < 0.001. F The expressions of OTUD5, p-mTOR, RNF186 and sestrin2 in the xenograft tumors were measured by immunohistochemistry. (Scale bar, 20 µm). G The expressions of OTUD5, p-mTOR, RNF186 and sestrin2 in the xenograft tumors were measured by Western blot. β-actin was used as the loading control. n = 6 mice per treatment group, data are presented as mean ± SD.
